The prevalence of Fabry disease in a Turkish population with chronic kidney patients

Tomar, Özdem Kavraz; Bal, Ayşe Zeynep; Şirali, Semahat Karahisar; Duranay, Murat; Korucu, Berfu; Güz, Galip; Akdağ, Seyit Ibrahim

doi:10.1007/s11255-023-03488-2

Cited by 1 publication

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the 3941 studies identified from the initial database search, 110 met the inclusion criteria and were analyzed for the systematic review and meta-analysis (Figure 1; Table SI). Among the included studies, 26 reports screened patients with left ventricular hypertrophy (LVH)/hypertrophic cardiomyopathy (HCM), 12–37 38 patients with end-stage renal disease (ESRD)/chronic kidney disease (CKD), 38–74 25 patients with stroke patients, 75–99 15 patients with newborns, 100–114 3 patients with small-fiber neuropathy patients, 115–117 and 3 patients with atrioventricular block or sinus node dysfunction requiring pacemaker implantation 118–120 (Figure 2).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Impact of GLA Variant Classification on the Estimated Prevalence of Fabry Disease: A Systematic Review and Meta-Analysis of Screening Studies

Monda,

Diana,

Graziani

et al. 2023

Circ: Genomic and Precision Medicine

View full text Add to dashboard Cite

BACKGROUND: The diagnosis of Fabry disease (FD) has relevant implications related to the management. Thus, a clear assignment of GLA variant pathogenicity is crucial. This systematic review and meta-analysis aimed to investigate the prevalence of FD in high-risk populations and newborns and evaluate the impact of different GLA variant classifications on the estimated prevalence of FD. METHODS: We searched the EMBASE and PubMed databases on February 21, 2023. Observational studies evaluating the prevalence of FD and reporting the identified GLA variants were included. GLA variants were re-evaluated for their pathogenicity significance using the American College of Medical Genetics and Genomics criteria and the ClinVar database. The pooled prevalence of FD among different settings was calculated. The study was registered on PROSPERO (CRD42023401663) and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. RESULTS: Of the 3941 studies identified, 110 met the inclusion criteria. The pooled prevalence of FD was significantly different according to the clinical setting and criteria used for the pathogenicity assessment. Using the American College of Medical Genetics and Genomics criteria, the pooled prevalence was 1.2% in patients with left ventricular hypertrophy/hypertrophic cardiomyopathy (26 studies; 10 080 patients screened), 0.3% in end-stage renal disease/chronic kidney disease (38 studies; 62 050 patients screened), 0.7% in stroke (25 studies; 15 295 patients screened), 0.7% in cardiac conduction disturbance requiring pacemaker (3 studies; 1033 patients screened), 1.0% in small-fiber neuropathy (3 studies; 904 patients screened), and 0.01% in newborns (15 studies; 11 108 793 newborns screened). The pooled prevalence was different if the GLA variants were assessed using the ClinVar database, and most patients with a discrepancy in the pathogenicity assignment carried 1 of the following variants: p.A143T, p.D313Y, and p.E66Q. CONCLUSIONS: This systematic review and meta-analysis describe the prevalence of FD among newborns and high-risk populations, highlighting the need for a periodic reassessment of the GLA variants in the context of recent clinical, biochemical, and histological data. REGISTRATION: URL: https://crd.york.ac.uk/PROSPERO/ ; Unique identifier: CRD42023401663.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Thirty-eight studies performing screening in patients with ESRD/CKD met the inclusion criteria, 38–74 providing data on the prevalence of FD among 62 050 patients screened.…”

Section: Resultsmentioning

confidence: 99%